Table 3.

The Incremental Cost-Effectiveness Ratio and Sensitivity Analysis

Variable	Range	$/LYa
Base-case		95,625
Interval of time between screening and diagnosis	t=3-months	194,644
	t=9-months	62,657
Number of program participants	n=189 (25% less)	127,118
	n=315 (25% more)	76,728
Age of women and PPV varied simultaneously	Age=40-49/ PPV=0.04	95,346
	Age=50-54/ PPV=0.09	47,889
	Age=55-59/ PPV=0.09	83,323
	Age=60-69/ PPV=0.17	65,376
	Age=70+/ PPV=0.19	89,361
Percent change in number of women who receive cancer diagnosis and treatment	p=15% increase	36,052
The methodological factor of accounting for total medical costs	LC=total medical costs	85,815b

^a2006 dollars, costs and effects are discounted by 3%, and LY stands for life-years.

^bundiscounted